RealTime Dynamix™: Psoriasis US Q2 2018 Spotlight

RealTime Dynamix™: Psoriasis US Q2 2018 Spotlight

Real time dynamix

Spherix’s Q2 update of RealTime Dynamix™: Psoriasis (US) reveals significant changes afoot in the current psoriasis biologic landscape. Year-over-year analysis indicates continued erosion of the established agents, such as AbbVie’s Humira, Amgen’s Enbrel, and Janssen’s Stelara, in favor of newer biologic entrants with alternate mechanisms of action (MOA). View complimentary highlights from this report below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.

All company, brand or product names and logos in this document are trademarks of their respective holders.

2018-06-15T15:19:01+00:00